10-K
Annual Report
ACTINIUM PHARMACEUTICALS, INC.
ATNM
NYSE
CIK: 1388320
File #: 001-36374
Balance Sheet
29 line items · 2 periods
XBRL
| Item | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
Assets | ||
Current Assets: | ||
Cash and cash equivalents | 76,677,000 | 108,910,000 |
Restricted cash – current | — | 396,000 |
Prepaid expenses and other current assets | 1,586,000 | 1,636,000 |
Total Current Assets | 78,263,000 | 110,942,000 |
Property and equipment, net of accumulated depreciation of $694 and $487 | 550,000 | 604,000 |
Restricted cash – long term | 313,000 | 302,000 |
Operating lease right-of-use assets | 2,289,000 | 2,341,000 |
Finance leases right-of-use assets | 30,000 | 3,000 |
Total Assets | 81,445,000 | 114,192,000 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 7,953,000 | 10,130,000 |
Operating leases current liability | 530,000 | 494,000 |
Finance leases current liability | 11,000 | 4,000 |
Total Current Liabilities | 8,494,000 | 10,628,000 |
Long-term license revenue deferred | 35,000,000 | 35,000,000 |
Long-term operating lease obligations | 1,553,000 | 2,083,000 |
Long-term finance lease obligations | 19,000 | — |
Total Liabilities | 45,066,000 | 47,711,000 |
Stockholders’ Equity: | ||
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 27,634,213 and 25,674,823 shares issued and outstanding at December 31, 2023 and 2022, respectively | 28,000 | 26,000 |
Additional paid-in capital | 373,934,000 | 355,220,000 |
Accumulated deficit | (337,583,000) | (288,765,000) |
Total Stockholders’ Equity | 36,379,000 | 66,481,000 |
Common Stock | 28,000 | 26,000 |
Additional Paid-In Capital | 373,934,000 | 355,220,000 |
Accumulated Deficit | (337,583,000) | (288,765,000) |
Total Liabilities and Stockholders’ Equity | 81,445,000 | 114,192,000 |